Brought to you by 
Isis, Alnylam in microRNA deal with Max Planck Society
03 Dec 2004
Executive Summary
The Max Planck Society has co-exclusively licensed Isis Pharmaceuticals and Alnylam Pharmaceuticals (develops therapeutics based on RNA interference, RNAi) rights to RNAi patent applications related to the more than 100 mammalian microRNAs discovered by Alnylam co-founder Thomas Tuschl.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Isis, Alnylam in microRNA deal with Max Planck Society
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice